Patents Examined by Noble E Jarrell
  • Patent number: 10538531
    Abstract: Provided herein are prodrugs of opioid receptor antagonists such as nalmefene and naltrexone, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of behavioral disorders.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: January 21, 2020
    Assignee: Nirsum Laboratories, Inc.
    Inventors: Michael W. Tusche, Nikej Shah
  • Patent number: 10538534
    Abstract: Analogs of largazole are described herein. Methods of treating cancer, blood disorders, autoimmune disease, and Alzheimer's Disease using largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 21, 2020
    Assignees: Colorado State University Research Foundation, Dana-Farber Cancer Institute, Inc., University of Notre Dame du Lac
    Inventors: Robert M. Williams, James E. Bradner, Dane Clausen, Olaf G. Wiest, Le Zhao, Christine Elizabeth Dunne
  • Patent number: 10537580
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 21, 2020
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Patent number: 10533015
    Abstract: Provided herein are prodrugs of opioid receptor antagonists such as nalmefene and naltrexone, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of behavioral disorders.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: January 14, 2020
    Assignee: Nirsum Laboratories, Inc.
    Inventors: Michael W. Tusche, Nikej Shah
  • Patent number: 10525055
    Abstract: Provided herein are prodrugs of opioid receptor antagonists such as nalmefene and naltrexone, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of behavioral disorders.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: January 7, 2020
    Assignee: Nirsum Laboratories, Inc.
    Inventors: Michael W. Tusche, Nikej Shah, Mingping Ding, Qiang Han, Liangliang Ji
  • Patent number: 10525058
    Abstract: The present invention provides a urea derivative or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea derivative or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: January 7, 2020
    Assignee: KYORIN PHARMACEUTICAL CO., LTD
    Inventors: Kiyoshi Fujii, Kentaro Umei, Hiroyasu Takahashi, Mitsuhito Shibasaki, Kohei Ohata
  • Patent number: 10526304
    Abstract: The present invention relates to nebivolol synthesis method and intermediate compound thereof. Specifically, the present invention relates to a method for synthesizing nebivolol, intermediate compound thereof, and a method for preparing the intermediate compound.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: January 7, 2020
    Assignee: ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.
    Inventor: Zhiguo Zheng
  • Patent number: 10525455
    Abstract: A catalyst composition comprising (a) a manganese-containing compound and (b) a carboxylic acid functionalized metal organic framework (MOF) compound; and a process for preparing an olefin oxide compound product including reacting (a) at least one olefin compound with (b) at least one oxidant in the presence of (c) the above catalyst composition.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: January 7, 2020
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: SonBinh T. Nguyen, Joseph T. Hupp, Omar K. Farha, Sergio J. Garibay
  • Patent number: 10520509
    Abstract: Reactive sulfur species have been recognized as an important regulator in redox biology, wherein the reactive sulfur species have been shown to be active in tumor suppressors, ion channels, and transcription factors. The disclosed invention is a novel composition of matter that allows for the detection of H2S and H2Sn species in living cells. These novel compositions represent significant progress in the field of chemical, H2S and H2Sn probes as they have both been successfully applied in the visualization sulfur species in living systems.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: December 31, 2019
    Assignee: WASHINGTON STATE UNIVERSITY
    Inventors: Ming Xian, Wei Chen
  • Patent number: 10517876
    Abstract: The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: December 31, 2019
    Assignee: CTI BIOPHARMA CORP.
    Inventors: Stephanie Blanchard, Cheng Hsia Angeline Lee, Harish Kumar Mysore Nagaraj, Anders Poulsen, Eric T. Sun, Yee Ling Evelyn Tan, Anthony Deodaunia William
  • Patent number: 10519112
    Abstract: The present invention provides: a method for producing a mixed sulfonic acid anhydride of the general formula (1) by reacting a sulfonic acid compound of the general formula (2) with a perfluoroalkyl sulfonic acid anhydride or a perfluoroalkyl sulfonic acid halide; and a method for producing a sulfonamide compound of the general formula (4) obtained by reacting an amine compound of the general formula (3) with a mixed sulfonic acid anhydride of the general formula (1).
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: December 31, 2019
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Yasuhito Yamamoto, Masayoshi Oue, Masahiko Hagihara, Yukinori Wada, Gen Mizuno, Yasunori Tsuzaki, Kenichi Arai
  • Patent number: 10508114
    Abstract: The present invention relates to compounds having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opiod receptor and more particularly to spiro-isoquinoline-4,4?-piperidine compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: December 17, 2019
    Assignee: ESTEVE PHARMACEUTICALS, S.A.
    Inventor: Carmen Almansa-Rosales
  • Patent number: 10500207
    Abstract: The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: December 10, 2019
    Assignee: AC IMMUNE SA
    Inventors: Heiko Kroth, Cotinica Hamel, Pascal Benderitter, Wolfgang Froestl, Nampally Sreenivasachary, Andreas Muhs
  • Patent number: 10501443
    Abstract: Disclosed in the present invention is a type of pyridone compounds as c-met inhibitors, and specifically disclosed is a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: December 10, 2019
    Assignee: FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.
    Inventors: Xiongbin Xu, Gang Li, Charles Z. Ding, Lihong Hu, Guoping Hu, Jian Li, Shuhui Chen, Zhigang Chi, Kun Wang
  • Patent number: 10501472
    Abstract: The invention relates to a novel method to isolate a natural product, a flavonoid namely inoscavin A from a Sri Lankan mushroom, medicinal preparation thereof to treat rhabdomyosarcoma cancer condition. This compound was isolated from the terrestrial basidiomycete Fulviformes fastuosus for the first time. The isolation method of the inoscavin A comprises the following steps of: (1) carrying out sonication extraction of pulverized specimen by methanol; (2) partitioning in to hexane, dichloromethane and ethyl acetate respectively by liquid-liquid extraction 3) fractionation using normal phase silica gel column chromatography 4) purification using preparative high performance liquid chromatography (HPLC) to obtain flavonoid compound inoscavin A in substantially purified form (?98%). In vitro cytotoxicity experiments demonstrated that the composition comprising inoscavin A strongly induced the apoptosis of human rhabdomyosarcoma (RD) cells compared to the cytotoxicity produced on normal epithelial cells (CC-1).
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: December 10, 2019
    Inventors: Dilusha Fernando, Ravi Wijesundera, Preethi Soysa, Dilip de Silva, Chandrika Nanayakkara, Achyut Adhikari
  • Patent number: 10501481
    Abstract: The present invention relates to heterocyclic compounds, their process of preparation, pharmaceutical compositions comprising these compounds and use thereof, optionally in combination with other antibacterial agents and/or beta-lactam compounds, for the prevention or treatment of bacterial infections. The present invention also relates to the use of these compounds as ?-lactamase inhibitors and/or as antibacterial agents.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: December 10, 2019
    Assignee: MUTABILIS
    Inventors: Julie Brias, Sophie Chasset, Francis Chevreuil, Nicolas Lecointe, Benôit Ledoussal, Frédéric Le Strat, Sophie Vomscheid, Sébastien Richard, Fabien Faivre, Julien Barbion, Audrey Caravano, Géraldine Le Fralliec, Christophe Simon
  • Patent number: 10487086
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: November 26, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Corte, Tianan Fang, Carl P. Decicco, Donald J. P. Pinto, Karen A. Rossi, Zilun Hu, Yoon Jeon, Mimi L. Quan, Joanne M. Smallheer, Yufeng Wang, Wu Yang
  • Patent number: 10485791
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: November 26, 2019
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Patent number: 10472365
    Abstract: The invention relates to besylate salts of the compound of formula (I): Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: November 12, 2019
    Assignee: PAION UK LIMITED
    Inventors: Gary Stuart Tilbrook, Louisa Jane Quegan
  • Patent number: 10463749
    Abstract: Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: November 5, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Thomas Nittoli, Thomas P. Markotan